675 articles in this topic
A new AHA scientific statement outlines evidence-based strategies to optimize heart failure care for older adults navigating frailty, polypharmacy, and multimorbidity.
An 80-week Amgen-sponsored Phase 3 trial evaluated evolocumab's safety and efficacy in pediatric patients aged 10–17 with inherited high LDL cholesterol.
Inflammation and blood sugar levels that deviate from what BMI predicts can dramatically shift heart failure risk, even at identical body weights.
A Phase 2 trial tests whether a fixed-dose combination pill can safely lower LDL cholesterol in people with type 2 diabetes.
A Phase 3 trial pits monthly lerodalcibep against evolocumab in homozygous familial hypercholesterolemia patients over 24 weeks.
A landmark AHA scientific statement tackles inconsistent cardiovascular safety reporting in oncology trials with a unified framework.
Merck's CETP inhibitor anacetrapib was evaluated alongside statin therapy to assess LDL-C lowering and HDL-C raising in hypercholesterolemia patients.
A Saudi Arabia survey reveals alarming gaps in ApoB testing knowledge among physicians and pharmacists, despite clear guideline recommendations.
A major NIH-backed study finds that daily low-dose aspirin does not extend healthy lifespan in older people, challenging a long-held preventive health belief.
A Lancet review reveals visual blood loss estimation misses 52% of PPH cases and outlines six avoidable delays that determine survival.
A Phase 2 trial pits NNC0385-0434 tablets against evolocumab injections in high-risk cardiovascular patients — could a daily pill replace the shot?
Amgen's siRNA therapy olpasiran targets lipoprotein(a), a stubborn cardiovascular risk factor with no approved treatments.
